MCID: BNS001
MIFTS: 35

Bone Osteosarcoma malady

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Bone Osteosarcoma

Aliases & Descriptions for Bone Osteosarcoma:

Name: Bone Osteosarcoma 12 14
Osteosarcoma of Bone 12 69
Primary Osteosarcoma of Bone 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3376
NCIt 47 C53707
SNOMED-CT 64 307576001
UMLS 69 C0585442

Summaries for Bone Osteosarcoma

MalaCards based summary : Bone Osteosarcoma, also known as osteosarcoma of bone, is related to osteosarcoma, somatic and bone cancer. An important gene associated with Bone Osteosarcoma is NKX3-2 (NK3 Homeobox 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Mitotic G1-G1/S phases. The drugs Succinylcholine and Radium Ra 223 dichloride have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Bone Osteosarcoma

Diseases related to Bone Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
id Related Disease Score Top Affiliating Genes
1 osteosarcoma, somatic 10.9
2 bone cancer 10.9
3 primary bone cancer 10.9
4 rommen mueller sybert syndrome 10.2 CDK4 MDM2
5 primary eye hypotony 10.2 CDK4 MDM2
6 osteomyelitis 10.2 CDK4 MDM2
7 amelogenesis imperfecta-gingival hyperplasia syndrome 10.2 CDK4 MDM2
8 aortic aneurysm 10.2 CDK4 MDM2
9 blood protein disease 10.2 CDK4 MDM2
10 apocrine sweat gland neoplasm 10.2 CDK4 MDM2
11 bone leiomyosarcoma 10.2 CDK4 MDM2
12 localized hypertrophic neuropathy 10.2 CDK4 MDM2
13 episodic ataxia 10.2 CDK4 MDM2
14 intracranial liposarcoma 10.2 CDK4 MDM2
15 extraosseous osteosarcoma 10.2 CDK4 MDM2
16 house allergic alveolitis 10.2 CDK4 MDM2
17 pinta disease 10.2 CDK4 MDM2
18 hormone producing pituitary cancer 10.2 CDK4 MDM2
19 pleural lipoma 10.1 CDK4 MDM2
20 childhood immature teratoma of ovary 10.1 CDK4 MDM2
21 enchondromatosis dwarfism deafness 10.1 CDK4 MDM2
22 liposarcoma of the ovary 10.1 CDK4 MDM2
23 multifocal osteogenic sarcoma 10.1 CDK4 MDM2
24 interstitial lung disease 10.1 CDK4 MDM2
25 stickler syndrome, type i 10.1 CDK4 MDM2
26 extraocular retinoblastoma 10.1 CDK4 MDM2
27 integumentary system benign neoplasm 10.1 CDK4 MDM2
28 pulmonary immaturity 10.0 CDK4 MDM2
29 hypotrichosis 8 10.0 CDK4 MDM2 SPARC
30 rhabdomyosarcoma 2, alveolar 9.9 CDK4 MDM2
31 liposarcoma 9.9 CREB3L1 SATB2 SPARC
32 conventional central osteosarcoma 9.8 CDK4 EMILIN1 MDM2 SATB2
33 malignant fibrous histiocytoma of bone 9.8
34 brain stem angioblastoma 9.8 CDK4 MDM2 SATB2 SPARC
35 metachronous osteosarcoma of the bone 9.6 CDK4 EMILIN1 MDM2 SATB2 SPARC
36 fibrous dysplasia 9.6
37 chondrosarcoma 9.6
38 giant cell tumor 9.6
39 malignant giant cell tumor 9.6
40 fibrosarcoma 9.6
41 paget's disease of bone 9.6
42 bacterial vaginosis 9.4 CREB3L1 CYP4V2 MDM2 SATB2 SPARC
43 liposarcoma of bone 8.9 CDK4 CREB3L1 CYP4V2 EMILIN1 MDM2 NKX3-2

Graphical network of the top 20 diseases related to Bone Osteosarcoma:



Diseases related to Bone Osteosarcoma

Symptoms & Phenotypes for Bone Osteosarcoma

MGI Mouse Phenotypes related to Bone Osteosarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CDK4 CREB3L1 EMILIN1 MDM2 NKX3-2 SPARC
2 homeostasis/metabolism MP:0005376 9.7 CDK4 CREB3L1 CYP4V2 EMILIN1 MDM2 SATB2
3 limbs/digits/tail MP:0005371 9.26 MDM2 NKX3-2 SATB2 SPARC
4 skeleton MP:0005390 9.02 CREB3L1 MDM2 NKX3-2 SATB2 SPARC

Drugs & Therapeutics for Bone Osteosarcoma

Drugs for Bone Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Succinylcholine Approved Phase 4,Phase 1,Phase 2 306-40-1 5314
2
Radium Ra 223 dichloride Approved, Investigational Phase 4,Phase 1,Phase 2 444811-40-9
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
5 Lithium carbonate Phase 4 554-13-2
6 Neuromuscular Agents Phase 4,Phase 1,Phase 2
7 Neuromuscular Blocking Agents Phase 4,Phase 1,Phase 2
8 Neuromuscular Depolarizing Agents Phase 4,Phase 1,Phase 2
9 Tranquilizing Agents Phase 4,Phase 1
10 Antidepressive Agents Phase 4
11 Psychotropic Drugs Phase 4,Phase 1
12 Antimanic Agents Phase 4,Phase 1
13
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-02-2 5743
14
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
15
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
16
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
17
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 84093 441203 2767
18
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
19
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
20
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
21
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
22
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
23
Ifosfamide Approved Phase 2, Phase 3, Phase 1 3778-73-2 3690
24
Zoledronic acid Approved Phase 2, Phase 3, Phase 1 118072-93-8 68740
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Diphenhydramine Approved Phase 2, Phase 3 58-73-1, 147-24-0 3100
27
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
28
Mesna Approved Phase 3,Phase 1,Phase 2 3375-50-6 598
29
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
30
Promethazine Approved Phase 2, Phase 3 60-87-7 4927
31
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
32
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
33
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
34
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 1 284461-73-0 216239 406563
35
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
36 Sodium thiosulfate Approved Phase 3
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
39
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
40
Cefazolin Approved Phase 3 25953-19-9 656510 33255
41
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
42
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
43
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
44
Cyproheptadine Approved Phase 3 129-03-3 2913
45
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
47
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124 9877265
48
Doxil Approved June 1999 Phase 2, Phase 3, Phase 1 31703
49
Vatalanib Investigational Phase 2, Phase 3 212141-54-3 151194
50
Cobalt Phase 3,Phase 1,Phase 2 7440-48-4 104729

Interventional clinical trials:

(show top 50) (show all 410)
id Name Status NCT ID Phase
1 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
2 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
3 CAFE Study - Cancer Patient Fracture Evaluation Completed NCT00211237 Phase 4
4 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4
5 Radium-223 Dichloride Long-term Follow-up Program Recruiting NCT02312960 Phase 4
6 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3
7 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3
8 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
9 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
10 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3
11 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3
12 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3
13 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3
14 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3
15 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3
16 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
17 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
19 ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain Completed NCT00656305 Phase 3
20 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
21 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
22 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3
23 ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Recruiting NCT01459484 Phase 2, Phase 3
24 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Recruiting NCT02711007 Phase 2, Phase 3
25 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Recruiting NCT01091883 Phase 3
26 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Recruiting NCT01479283 Phase 3
27 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Recruiting NCT01916317 Phase 3
28 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Recruiting NCT02856048 Phase 2, Phase 3
29 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
30 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3
31 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3
32 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3
33 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3
34 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
35 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3
36 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3
37 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3
38 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
39 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
40 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
41 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3
42 A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma Unknown status NCT01002092 Phase 2
43 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2
44 Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma Unknown status NCT00689195 Phase 1, Phase 2
45 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2
46 The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells Unknown status NCT01868490 Phase 1, Phase 2
47 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2
48 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
49 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2
50 Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy Unknown status NCT00807261 Phase 2

Search NIH Clinical Center for Bone Osteosarcoma

Genetic Tests for Bone Osteosarcoma

Anatomical Context for Bone Osteosarcoma

MalaCards organs/tissues related to Bone Osteosarcoma:

39
Bone

Publications for Bone Osteosarcoma

Articles related to Bone Osteosarcoma:

id Title Authors Year
1
Orbital metastasis: a rare manifestation of scapular bone osteosarcoma. ( 25709781 )
2014
2
Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. ( 21207222 )
2011
3
Primary bone osteosarcoma in the pediatric age: state of the art. ( 16860938 )
2006
4
Treatment of a second bone osteosarcoma. 3 cases and an unusual MRI finding. ( 7976302 )
1994
5
Problems and pitfalls in the use of computed tomography for the local evaluation of long bone osteosarcoma: report on 30 cases. ( 3856325 )
1985
6
Computed tomography of long-bone osteosarcoma. ( 286376 )
1979
7
Long bone osteosarcoma in a rhesus monkey. ( 293317 )
1979
8
Malignant tumors primary in bone (osteosarcoma, chondrosarcoma, fibrosarcoma, malignant giant cell tumor). ( 5272232 )
1970

Variations for Bone Osteosarcoma

Expression for Bone Osteosarcoma

Search GEO for disease gene expression data for Bone Osteosarcoma.

Pathways for Bone Osteosarcoma

Pathways related to Bone Osteosarcoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.08 CDK4 CREB3L1 MDM2
2
Show member pathways
12.02 CDK4 CREB3L1 MDM2
3 11.27 CDK4 MDM2
4 11.1 CDK4 CREB3L1 MDM2
5 10.92 CDK4 MDM2
6 10.8 CDK4 MDM2
7 10.46 CDK4 MDM2

GO Terms for Bone Osteosarcoma

Biological processes related to Bone Osteosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to growth factor stimulus GO:0071363 9.37 MDM2 SPARC
2 regulation of gene expression GO:0010468 9.33 CDK4 MDM2 SATB2
3 positive regulation of cell cycle GO:0045787 9.32 CDK4 MDM2
4 cellular response to organic substance GO:0071310 9.26 MDM2 SATB2
5 negative regulation of cell cycle arrest GO:0071157 8.96 CDK4 MDM2
6 response to lead ion GO:0010288 8.62 CDK4 SPARC

Sources for Bone Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....